The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Novel treatment strategies for BRAF V600E-mutant NSCLC
Dabrafenib plus trametinib have demonstrated promising efficacy in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) and alternative doublet combinations based on existing melanoma therapies are current under investigation. Bruce Johnson, MD, Dana-Farber Cancer Institute, Boston, MA, describes the trial design of the ongoing Phase II PHAROS trial (NCT03915951), which aims to investigate encorafenib and binimetinib, a BRAF and MEK inhibitor respectively, in patients with BRAF V600E-mutant NSCLC. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
